Merz Aesthetics Sponsors Symposium Highlighting Market Trends With a Portfolio Approach at the 2025 Aesthetic and Anti-aging Medicine World Congress (AMWC)

24.3.2025 08:00:00 CET | Business Wire | Press Release

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, is set to unveil new data on its product portfolio and offer insights into the latest trends in the industry at the 2025 Aesthetic and Anti-Aging Medicine World Congress held in Monaco, France.

“Thanks to the scientific profile of our products, our portfolio continues to meet evolving expectations of physicians,” said Dr. Kerstin Olsson, Head of Medical Affairs in EMEA, “from routine procedures to cutting-edge treatments, we’re redefining innovation in the aesthetics industry”.

“We recognize that beauty is personal and unique to everyone. We are dedicated to understanding the needs of health care professionals and their patients,” said Gonzalo Mibelli, President, EMEA, Merz Aesthetics. “We look forward to sharing our latest data and vision for the future of medical aesthetics”.

Merz Aesthetics’ programming includes a sponsored symposium on March 28 from 14:00 - 16:00, The Evolution of Aesthetics: Foundations, Trends and Future, moderated by Dr. Mariana Muniz, featuring commentary from Dr. Martina Kerscher, Dr. Kate Goldie, Dr. Jani van Loghem, Dr. Nabil Fakih and Dr. Jonathan Kadouch. During the session, the group of experts will highlight emerging trends in medical aesthetics and demonstrate how solutions are tailored for personalized treatments.

In addition to the symposium, Merz Aesthetics is presenting six talks under the umbrella of MAX Merz Aesthetics Exchange, which are taking place at the booth P1, Level 1:

The Science of Connection: Using Synchrony to Improve Patient Communication; Joshua Bernstein, Neuroconsultant; Thursday, March 27; 13:15
Unlock your Social Media: Insights from a leading expert; Dr. Emi Arpa; Thursday, March 27; 13:45
Enhancing Lips: Tailored techniques based on age & gender; Dr. Awat Hassan; Thursday, March 27; 16:15
Mastering the Patient Journey; Vanessa Bird, Business Expert; Friday, March 28; 10:45
Radiesse: Unlock the Secret to a youthful-looking & smoother Décolleté; Dr. Rosalia Luketina; Friday, March 28; 13:15
Radiesse – Biostimulatory Scaffold in Regenerative Aesthetics – Nonclinical research; Dr. Ewelina Kaczuba; Dr. Yoana Dimitrova; Saturday, March 29; 10:45

Twenty e-posters will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts. They include:

Efficacy and Safety of IncobotulinumtoxinA in the treatment of Upper Facial Lines: Findings from two phase III randomized, double-blind, placebo-controlled studies - Tatjana Pavicic MD, Michael Gold MD, Martina Kerscher MD, Vladimir Sudimac MD, Petra Weissenberger MD, John Joseph MD
Long-term Durability of IncobotulinumtoxinA Treatment in the Upper Face as Reported by Global Aesthetic Improvement Scale - Michael H. Gold, MD; Andy Curry, PhD; Ivanti Galloway; Z. Paul Lorenc M.D., F.A.C.S.
Lifting and Structural Enhancement of Dermal Fillers with Cohesive Polydensified Matrix® Technology - Pia Vestweber, PhD; Yoana Dimitrova, MSc; Kay Marquardt, PhD; Thomas Hengl, PhD
Long-Term Skin Improvement through Combined MFU-V and CaHA Treatments - Tingsong Lim, MD; Meng Jun Ho, MD
The Cohesive Polydensified Matrix Hyaluronic Acid (CPM-HA) Gels Demonstrate Biomimetic Tissue Plane Adaptation: An Integrative Analysis of Physiochemical Properties - Gabriela Casabona, MD; Radovan Vukicevic, PhD; Angela Prager, PhD; Mimi R. Borrelli, MBBS, PhD, MSc

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250324799451/en/

Contacts

Media Contact
Diana Trojanus - EMEA Communications - Merz Aesthetics GmbH - Eckenheimer
Landstraße 100, 60318 Frankfurt am Main, Germany, Media@merz.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AlbaCore Launches its Senior Direct Lending Strategy, with Commitments from ADIA and Mitsubishi UFJ Trust and Banking Corporation27.3.2025 08:00:00 CET | Press Release

European credit specialist AlbaCore Capital Group (“AlbaCore”) today announces the launch of a new Senior Direct Lending Strategy (“the Strategy”), having secured anchor investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and Mitsubishi UFJ Trust and Banking Corporation (the “Trust Bank”). AlbaCore has successfully completed its first close, bringing together an expected $1.8 billion in investable capital. With the launch of the Strategy, AlbaCore is well positioned to take advantage of the growing opportunity set to finance loans, further expanding its market presence and delivering enhanced value to clients globally. “Securing commitments from ADIA and the Trust Bank for the first vintage of our Senior Direct Lending Strategy is a testament to the attractiveness of the opportunity set in the market and how well positioned AlbaCore is to take advantage of it,” said David Allen, Managing Partner and Chief Investment Officer at AlbaCore. The Strateg

Nederlandse Innovatie Maatschappij (NIM) Leads H2ESTIA Project: The Future of Emission-Free Cargo Transport27.3.2025 07:00:00 CET | Press Release

The maritime industry is taking a large step toward sustainability with the launch of the H2ESTIA Project, a groundbreaking initiative to develop the world’s first zero-emission general cargo ship powered by liquid hydrogen. Led by the Dutch Innovation Company (NIM – www.nim-bv.nl ) and supported by the Dutch Ministry of Infrastructure and Water Management, this initiative is a key pillar of the Maritime Masterplan, setting a new standard for decarbonizing European maritime logistics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326530510/en/ Concept design of the zero-emission hydrogen powered bulk carrier The project focuses on designing, constructing, and demonstrating a hydrogen-powered cargo vessel that will operate in the North Sea and beyond. Managed by Van Dam Shipping, the ship is designed to transport bulk goods, eliminating harmful emissions and redefining the future of sustainable shipping. At the heart of t

IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale27.3.2025 07:00:00 CET | Press Release

IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production will use IFF’s Designed Enzymatic Biomaterial™ (DEB) platform technology, integrated at the IFF biorefinery in Kotka, Finland. "Our partnership with Kemira has reached a significant milestone, enabling us to scale the production of groundbreaking biobased materials to meet the large and growing demand for high-performing and sustainable alternatives to fossil-derived polymers," said Erik Fyrwald, IFF CEO. "IFF’s DEB technology not only guarantees superior purity and consistency compared to traditional biopolymers but also en

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis27.3.2025 07:00:00 CET | Press Release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health Canada to launch the Phase 2a INFLAM MOTION “Proof-of-Concept” study for 4P004 in patients with knee osteoarthritis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326675460/en/ Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Canada. It will enroll 129 patients to evaluate, for the first time, the efficacy of 4P004 in individuals with knee osteoarthritis. 4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti

Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-0127.3.2025 07:00:00 CET | Press Release

Curatis Holding AG (SIX:CURN, ‘Curatis’) reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution business by 30% per cent to CHF 9.5m in the full year 2024 compared to 2023. Further key statements: Curatis is increasing the estimate for the number of patients addressed in the lead project C-PTBE-01 by a factor of 20. The reason for this is that Curatis can apply for a biologics licence for C-PTBE-01, which grants 12 years of market protection in the USA. This suggests an expansion of the indications, namely from PTBE in diffuse midline glioma (DMG) in children to PTBE in other primary and metastatic brain tumours in children and adults. A meeting with the US Food and Drug Administration (FDA) to discuss a potential pivotal Phase III trial for C-PTBE-01 is in preparation and is targeted for Q2. The strong cash position of CHF 3m at the end of the year combined with the positive, growing c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom